Metabotropic Glutamate Receptor 2 and 3 Gene Expression in The Human Prefrontal Cortex and Mesencephalon in Schizophrenia

REFERENCES

• Akil M., Kolachana B. S., Rothmond D. A., Hyde T. M., Weinberger D. R., Kleinman J. E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. Journal of Neuroscience 2003; 23: 2008–2013
   PubMed Web of Science ®Google Scholar
• Anwyl R. Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Researchearch. Brain Researchearch Reviews 1999; 29: 83–120
   PubMedGoogle Scholar
• Bishop J. R., Ellingrod V. L., Moline J., Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophrenia Research 2005; 77: 253–260
   PubMed Web of Science ®Google Scholar
• Buchanan R. W., Vladar K., Barta P. E., Pearlson G. D. Structural evaluation of the prefrontal cortex in schizophrenia. American Journal of Psychiatry 1998; 155: 1049–1055
   PubMed Web of Science ®Google Scholar
• Buchsbaum M. S., Schoenknecht P., Torosjan Y., Newmark R., Chu K. W., Mitelman S., et al. Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. Annals of General Psychiatry 2006; 5: 19
   PubMedGoogle Scholar
• Cartmell J., Monn J. A., Schoepp D. D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl) 2000; 148: 423–429
   Google Scholar
• Chen Q., He G., Chen Q., Wu S., Xu Y., Feng G., et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophrenia Research 2005; 73: 21–26
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical power analysis for the behavioral sciences 2nd, et al. Lawrence Earlbaum Associates, Hillsdale, NJ 1988
   Google Scholar
• Crook J. M., Akil M., Law B. C., Hyde T. M., Kleinman J. E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Molecular Psychiatry 2002; 7: 157–164
   Google Scholar
• Davis K. L., Stewart D. G., Friedman J. I., Buchsbaum M., Harvey P. D., Hof P. R., et al. White matter changes in schizophrenia: Evidence for myelin-related dysfunction. Archives of General Psychiatry 2003; 60: 443–456
   PubMed Web of Science ®Google Scholar
• Egan M. F., Straub R. E., Goldberg T. E., Yakub I., Callicott J. H., Hariri A. R., et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Science United States of America 2004; 101: 12604–12609
   PubMed Web of Science ®Google Scholar
• Follett P. L., Rosenberg P. A., Volpe J. J., Jensen F. E. NBQX attenuates excitotoxic injury in developing white matter. Journal of Neuroscience 2000; 20: 9235–9241
   PubMed Web of Science ®Google Scholar
• Fujii Y., Shibata H., Kikuta R., Makino C., Tani A., Hirata N., et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatric Genetic 2003; 13: 71–76
   PubMed Web of Science ®Google Scholar
• Gupta D. S., McCullumsmith R. E., Beneyto M., Haroutunian V., Davis K. L., Meador-Woodruff J. H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005; 57: 123–131
   PubMed Web of Science ®Google Scholar
• Hakak Y., Walker J. R., Li C., Wong W. H., Davis K. L., Buxbaum J. D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Science United States of America 2001; 98: 4746–4751
   PubMed Web of Science ®Google Scholar
• Haroutunian V., Katsel P., Dracheva S., Stewart D., Davis K. Variations in oligodendrocyte-related gene expression across multiple cortical regions: Implications for the pathophysiology of schizophrenia. The International Journal of Neuropsychopharmacology 2007; 10: 565–573
   PubMed Web of Science ®Google Scholar
• Hassel B., Boldingh K. A., Narvesen C., Iversen E. G., Skrede K. K. Glutamate transport, glutamine synthetase and phosphate-activated glutaminase in rat CNS white matter. A quantitative study. Journal of Neurochemistry 2003; 87: 230–237
   PubMed Web of Science ®Google Scholar
• Karadottir R., Cavelier P., Bergersen L. H., Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438: 1162–1166
   PubMed Web of Science ®Google Scholar
• Kriegler S., Chiu S. Y. Calcium signaling of glial cells along mammalian axons. Journal of Neuroscience 1993; 13: 4229–4245
   Google Scholar
• Krystal J. H., Abi-Saab W., Perry E., D’Souza D. C., Liu N., Gueorguieva R., et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005; 179: 303–309
   PubMed Web of Science ®Google Scholar
• Kubicki M., McCarley R. W., Shenton M. E. Evidence for white matter abnormalities in schizophrenia. Current Opinion Psychiatry 2005; 18: 121–134
   PubMedGoogle Scholar
• Lim K. O., Adalsteinsson E., Spielman D., Sullivan E. V., Rosenbloom M. J., Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Archives of General Psychiatry 1998; 55: 346–352
   PubMed Web of Science ®Google Scholar
• Lim K. O., Hedehus M., Moseley M., de Crespigny A., Sullivan E. V., Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Archives of General Psychiatry 1999; 56: 367–374
   PubMed Web of Science ®Google Scholar
• Makoff A., Volpe F., Lelchuk R., Harrington K., Emson P. Molecular characterization and localization of human metabotropic glutamate receptor type 3. Brain Researchearch Molecular Brain Researchearch 1996; 40: 55–63
   Google Scholar
• Marenco S., Steele S. U., Egan M. F., Goldberg T. E., Straub R. E., Sharrief A. Z., et al. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. American Journal of Psychiatry 2006; 163: 740–742
   PubMedGoogle Scholar
• Marti S. B., Cichon S., Propping P., Nothen M. Metabotropic glutamate receptor 3 (GRM3). gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. American Journal of Medical Genetics 2002; 114: 46–50
   PubMed Web of Science ®Google Scholar
• Matute C., Alberdi E., Domercq M., Perez-Cerda F., Perez-Samartin A., Sanchez-Gomez M. V. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends in Neuroscience 2001; 24: 224–230
   PubMed Web of Science ®Google Scholar
• Matute C., Domercq M., Fogarty D. J., Pascual de Zulueta M., Sanchez-Gomez M. V. On how altered glutamate homeostasis may contribute to demyelinating diseases of the CNS. Advances in Experimental Medicine and Biology 1999; 468: 97–107
   Google Scholar
• McDonald J. W., Althomsons S. P., Hyrc K. L., Choi D. W., Goldberg M. P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Natural Medicine 1998; 4: 291–297
   PubMed Web of Science ®Google Scholar
• McRitchie D. A., Halliday G. M., Cartwright H. Quantitative analysis of the variability of substantia nigra pigmented cell clusters in the human. Neuroscience 1995; 68: 539–551
   PubMed Web of Science ®Google Scholar
• Mitkus S. N., Hyde T. M., Caruso M., Vakkalanka R., Kolachana B., Weinberger D. R., Kleinman J. E., Lipska B. K. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophrenia Research 2008; 98: 129–138
   PubMed Web of Science ®Google Scholar
• Moghaddam B., Adams B. W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349–1345
   PubMed Web of Science ®Google Scholar
• Norton N., Williams H. J., Dwyer S., Ivanov D., Preece A. C., Gerrish A., et al. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 2005; 5: 23
   PubMed Web of Science ®Google Scholar
• Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 1993a; 53: 1009–1018
   PubMed Web of Science ®Google Scholar
• Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study. Journal of Computer Neurology 1993b; 335: 252–667
   PubMed Web of Science ®Google Scholar
• Ohnuma T., Augood S. J., Arai H., McKenna P. J., Emson P. C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Researchearch Molecular Brain Researchearch 1998; 56: 207–217
   PubMedGoogle Scholar
• Patil S. T., Zhang L., Martenyi F., Lowe S. L., Jackson K. A., Andreev B. V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Natural Medicine 2007; 13: 1102–1107
   PubMed Web of Science ®Google Scholar
• Paxinos G., Huang X. F. Atlas of the Human Brainstem, et al. Academic Press, San Diego, CA 1995; 57
   Google Scholar
• Phillips T., Rees S., Augood S., Waldvogel H., Faull R., Svendsen C., et al. Localization of metabotropic glutamate receptor type 2 in the human brain. Neuroscience 2000; 95: 1139–1156
   Google Scholar
• Rajkowska G., Goldman-Rakic P. S. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. Cerebral Cortex 1995; 5: 323–337
   PubMed Web of Science ®Google Scholar
• Sanfilipo M., Lafargue T., Rusinek H., Arena L., Loneragan C., Lautin A., et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: Relationship to negative symptoms. Archives of General Psychiatry 2000; 57: 471–480
   PubMed Web of Science ®Google Scholar
• Sartorius L. J., Nagappan G., Lipska B. K., Lu B., Sei Y., Ren-Patterson R., et al. Alternative splicing of human metabotropic glutamate receptor 3. Journal of Neurochemistry 2006; 96: 1139–1148
   PubMed Web of Science ®Google Scholar
• Sesack S. R., Pickel V. M. In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Research 1990; 527: 266–279
   Google Scholar
• Smiley, Goldman-Rakic. Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: A laminar analysis using the silver-enhanced diamonobenzidine sulfide immunolabelling technique. Cerebral Cortex 1993; 3: 223–238
   Google Scholar
• Smith Y., Bennett B. D., Bolam J. P., Parent A., Sadikot A. F. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. The Journal of Comparative Neurology 1994; 344: 1–19
   PubMed Web of Science ®Google Scholar
• Steel R. M., Bastin M. E., McConnell S., Marshall I., Cunningham-Owens D. G., Lawrie S. M., et al. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Research 2001; 106: 161–170
   PubMed Web of Science ®Google Scholar
• Tanabe Y., Nomura A., Masu M., Shigemoto R., Mizuno N., Nakanishi S. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. Journal of Neuroscience 1993; 13: 1372–1378
   PubMed Web of Science ®Google Scholar
• Testa C. M., Standaert D. G., Young A. B., Penney J. B., Jr. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. Journal of Neuroscience 1994; 14: 3005–3018
   PubMed Web of Science ®Google Scholar
• Testa C. M., Friberg I. K., Weiss S. W., Standaert D. G. Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. The Journal of Comparative Neurology 1998; 390: 5–19, .14
   Google Scholar
• Whitfield H. J., Jr., Brady L. S., Smith M. A., Mamalaki E., Fox R. J., Herkenham M. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: A detailed protocol. Cellular and Molecular Neurobiology 1990; 10: 145–157
   PubMed Web of Science ®Google Scholar
• Vezina P., Kim J. H. Metabotropic glutamate receptors and the generation of locomotor activity: Interactions with midbrain dopamine. Neuroscience Biobehavior Review 1999; 23: 577–589
   Google Scholar
• Walterfang M., Wood S. J., Velakoulis D., Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neuroscience Biobehavior Review 2006; 30: 918–948
   PubMed Web of Science ®Google Scholar
• Werner P., Pitt D., Raine C. S. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Annals of Neurology 2001; 50: 169–180
   PubMed Web of Science ®Google Scholar